Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KARKHANEH R.; TORABI H.R.; KHODABANDEH A.R.; ROOHIPOOR R.; RIAZI ESFAHANI M.; SHAHSAVARI M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: BINA Year:2018 | Volume:23 | Issue:4 Page(s): 242-247

Download Full-Text

Persian Verion

View:

983

Download:

Cites:

Information Journal Paper

Title

Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity

Author(s)

Keywords

Anti􀀀Vascular Endothelial Growth FactorQ1

Intravitreal BevacizumabQ1

Retinopathy of PrematurityQ1

TreatmentQ1

Zone IQ1

Abstract

Purpose: To evaluate the efficacy of Intravitreal Bevacizumab for the Treatment of type 1 Retinopathy of Prematurity (ROP) in Zone I. Methods: Preterm infants with type 1 ROP in Zone I (Zone I ROP, any stage with plus disease or Zone I ROP, stage 3 without plus disease) were enrolled in this prospective study. Intravitreal Bevacizumab (0. 625 mg/0. 025 ml) was injected under topical anesthesia. The patients were followed-up weekly for 4 weeks and, then, biweekly till 90 weeks gestational age. Results: Seventy eyes of 35 patients with type 1 ROP in Zone I were enrolled. At a gestational age of 90 weeks, ROP regressed with complete or near􀀀 complete peripheral retinal vascularization, in 82. 9% of eyes after a single injection and in 92. 9% of eyes after up to two injections. In 5 eyes (7. 1%), ROP progressed to stage 4B or 5, so that surgical management was required. There were no major complications such as endophthalmitis, cataract, or vitreous hemorrhage after injection. Conclusion: Intravitreal Bevacizumab injection is an effective method for the management of patients with Zone I ROP requiring Treatment; however, some cases may progress to more advanced stages and require surgical management. Close monitoring for recurrence or progression is necessary. Eyes with persistent Zone I ROP may progress to advanced stages when treated with Intravitreal Bevacizumab injection and re􀀀 Treatment may be needed.

Cites

No record.

References

No record.

Cite

APA: Copy

KARKHANEH, R., TORABI, H.R., KHODABANDEH, A.R., ROOHIPOOR, R., RIAZI ESFAHANI, M., & SHAHSAVARI, M.. (2018). Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity. BINA, 23(4 ), 242-247. SID. https://sid.ir/paper/42543/en

Vancouver: Copy

KARKHANEH R., TORABI H.R., KHODABANDEH A.R., ROOHIPOOR R., RIAZI ESFAHANI M., SHAHSAVARI M.. Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity. BINA[Internet]. 2018;23(4 ):242-247. Available from: https://sid.ir/paper/42543/en

IEEE: Copy

R. KARKHANEH, H.R. TORABI, A.R. KHODABANDEH, R. ROOHIPOOR, M. RIAZI ESFAHANI, and M. SHAHSAVARI, “Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity,” BINA, vol. 23, no. 4 , pp. 242–247, 2018, [Online]. Available: https://sid.ir/paper/42543/en

Related Journal Papers